{
  "nctId": "NCT01183884",
  "briefTitle": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma",
  "officialTitle": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma: A Phase II Study",
  "protocolDocument": {
    "nctId": "NCT01183884",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2014-08-06",
    "uploadDate": "2019-10-25T12:30",
    "size": 1003169,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01183884/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 46,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2010-08",
    "completionDate": "2018-11-09",
    "primaryCompletionDate": "2018-11-09",
    "firstSubmitDate": "2010-08-16",
    "firstPostDate": "2010-08-18"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Diagnosis of NB as defined by a) histopathology (confirmed by the MSKCC Department of Pathology), or b) BM metastases or MIBG-avid lesion(s) plus high urine catecholamine levels.\n* High-risk NB as defined by risk-related treatment guidelines1 and the International NB Staging System,89 i.e., stage 4 with (any age) or without (\\> or = to 18 months of age) MYCN amplification, MYCN-amplified stage 2 or stage 3 (any age), or MYCN-amplified stage 4S.\n* The patients are in \\>2nd CR/VGPR, including no measurable MIBG-avid soft tissue tumor assessable for response.\n* Signed informed consent indicating awareness of the investigational nature of this program.\n\nExclusion Criteria:\n\n* Creatinine \\> 3.0 mg/dL\n* ALT, AST and Alkaline Phosphatase \\> 5.0 times the upper limit of normal\n* Bilirubin \\> 3.0 mg/dL\n* Patients with grade 3 or higher toxicities (using the CTCAE v34.0) related to cardiac, neurological, pulmonary or gastrointestinal function as determined by physical exam. Patients must have normal blood pressure for age.\n* Progressive disease\n* History of allergy to mouse proteins\n* Active life-threatening infection.\n* Human anti-mouse antibody (HAMA) titer \\>1000 Elisa units/ml.\n* Inability to comply with protocol requirements.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Months",
    "stdAges": [
      "CHILD",
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Assess the Impact of High-dose 3F8/GM-CSF on Relapse-free Survival",
        "description": "in patients in second or greater complete or very good partial remission, but at high risk of additional relapse.",
        "timeFrame": "2 years"
      }
    ],
    "secondary": [
      {
        "measure": "Apply Real-time Quantitative RT-PCR to Test the Hypothesis That the Minimal Residual Disease Content of Bone Marrow",
        "description": "after the first treatments with 3F8/GMCSF has significant prognostic impact on relapse-free survival.",
        "timeFrame": "2 years"
      },
      {
        "measure": "Monitor Safety of the High-dose Antibody Treatment",
        "description": "to assure no side-effects or noxious sequelae develop or emerge that were not seen in the prior phase I study.",
        "timeFrame": "2 years"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 2,
      "otherCount": 0,
      "totalCount": 3
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 24,
    "complexityCategory": "Simple"
  },
  "collectionDate": "2025-09-22T02:30:47.071Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}